Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Tran K, Coyle K, Jabr MF, et al. Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Mar.
Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness [Internet].
Show detailsTable 240. Costs by Cost Category for Monotherapy in Functional Class II
Table 241. Costs by Cost Category for Monotherapy in Functional Class III
Table 242. Costs by Cost Category for Monotherapy in Functional Class IV
Table 243. Costs by Cost Category for Add-on Therapies in Functional Class II
Table 244. Costs by Cost Category for Add-on Therapies in Functional Class III
Table 245. Costs by Cost Category for Add-on Therapies in Functional Class IV
- BREAKDOWN OF COSTS BY COST CATEGORY - Drugs for Pulmonary Arterial Hypertension:...BREAKDOWN OF COSTS BY COST CATEGORY - Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness
- REFERENCES - Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Sa...REFERENCES - Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness
- Rattus norvegicus ELAV like RNA binding protein 1 (Elavl1), mRNARattus norvegicus ELAV like RNA binding protein 1 (Elavl1), mRNAgi|157818152|ref|NM_001108848.1|Nucleotide
- Saccharomyces cerevisiae S288C siderophore transporter (SIT1), partial mRNASaccharomyces cerevisiae S288C siderophore transporter (SIT1), partial mRNAgi|398364220|ref|NM_001178880.3|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...